Paurush Babbar
Urology · Cincinnati, OHNPI 1770826695
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (35.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 97.5% of it on its own, with 36 other manufacturers making up the rest. Among urology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 468 payments — averaging $299.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$137K
- Astellas Pharma US Inc$372
- Endo USA, Inc.$353
- Sumitomo Pharma America, Inc.$228
- Bayer$214
- Endo Pharmaceuticals Inc.$208
- plus $2K from 31 others
What the payments were for
- Consulting fees$31,66923%
- Speaking & faculty fees$36,09426%
- Grants$50,00036%
- Travel & lodging$9,3977%
- Food & beverage$12,9319%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 299 | $136,693 |
| Astellas Pharma US Inc | 20 | $372 |
| Endo USA, Inc. | 13 | $353 |
| Sumitomo Pharma America, Inc. | 10 | $228 |
| Bayer | 12 | $214 |
| Endo Pharmaceuticals Inc. | 12 | $208 |
| Dendreon Pharmaceuticals LLC | 6 | $155 |
| Urogen Pharma, Inc. | 6 | $147 |
| Antares Pharma, Inc. | 7 | $135 |
| Axonics, Inc. | 8 | $132 |
| Accord Healthcare, Inc. | 7 | $119 |
| Merck | 4 | $109 |
| Immunitybio, Inc. | 3 | $107 |
| Progenics Pharmaceuticals, Inc. | 4 | $91 |
| Urovant Sciences Inc | 5 | $90 |
| Tolmar Pharmaceuticals, Inc. | 5 | $83 |
| Hollister Incorporated | 3 | $79 |
| Laborie Medical Technologies Corp. | 2 | $78 |
| Acerus Pharmaceuticals Corporation | 6 | $77 |
| Clarus Therapeutics Inc. | 7 | $75 |
| Johnson & Johnson | 4 | $71 |
| AbbVie(2 entities) | 3 | $68 |
| Tolmar, Inc. | 3 | $66 |
| Novartis | 2 | $57 |
| Teleflex LLC | 3 | $53 |
| Convatec Inc. | 1 | $48 |
| Pfizer | 3 | $43 |
| BD | 1 | $29 |
| Procept Biorobotics Corporation | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Myovant Sciences Inc. | 1 | $20 |
| Olympus America Inc. | 1 | $19 |
| Coloplast | 1 | $18 |
| Neotract Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $16 |
| Rigicon,inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL ERECTILE DYSFUNCTION$66,286
- TACTRA$14,250
- AdVance XP$10,171
- AMS 700$2,379
- AMS$1,898
- AMS 700 CXR RTE KIT$1,488
- AMS 800 Artificial Urinary Sphincter$1,298
How this compares
$140,146 in reported general payments places this provider in the 95th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 60 | $61,213 |
| Trospium Chloride ErTrospium Chloride | 14 | $2,598 |
| Tamsulosin Hcl | 230 | $2,141 |
| Cabergoline | 18 | $1,614 |
| Finasteride | 72 | $959 |
| Testosterone Cypionate | 19 | $743 |
| Tadalafil | 11 | $661 |
| Clobetasol Propionate | 15 | $602 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 109 | $393 |
| Nystatin | 12 | $290 |
| Levofloxacin | 41 | $289 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $212 |
| Oxycodone Hcl | 66 | $107 |
| Fluconazole | 13 | $58 |
| Meloxicam | 18 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $372 | $61,21360 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 485 urology providers in Ohio.
Other urology in Cincinnati
- Abhinav SidanaCincinnati$174K
- Marc PliskinCincinnati$108K
- Stephen BennettCincinnati$38K
- Michael RousseauCincinnati$26K
- Kamal PoharCincinnati$20K
- Ryan FlynnCincinnati$16K
- Lawrence GervasiMiddleburg Heights$1.1M
- Howard GoldmanCleveland$721K
- Ronney AbazaWorthington$374K
- Sriharan SivalingamCleveland$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.